Pharma Video Production Cost Guide | Make It Real Production

TL;DR: UK pharmaceutical companies typically invest £8,000–£65,000 per production, with costs driven by ABPI Code compliance review, MHRA-aligned claims substantiation, and patient-consent workflows that can add 4–8 weeks to a standard timeline. Whether you are recruiting participants for a Phase III oncology trial, training medical science liaisons on a newly licensed compound, or creating a branded patient-support film for a rare disease indication, pharmaceutical video demands a production partner who understands the regulatory environment as well as the camera. Generic agencies create regulatory risk. This guide explains what compliant pharma video costs, why it costs that much, and how to commission it correctly.

Why the Pharmaceutical Sector Needs Specialist Video Production

The UK pharmaceutical industry operates under one of the tightest promotional codes in the world. The ABPI Code of Practice — administered by the Prescription Medicines Code of Practice Authority (PMCPA) — governs every promotional communication directed at healthcare professionals, including video. Beyond promotional content, MHRA guidance on advertising medicinal products sets hard limits on what may be communicated to patients and the general public.

The regulatory stakes are high. A single non-compliant video can trigger a PMCPA complaint, a formal investigation and reputational damage lasting years. In 2023, the PMCPA published 87 case reports, of which 34 related to digital and multimedia content — a 22% increase on 2021. At the same time, clinical-trial recruitment videos have been shown to increase enrolment rates by up to 35% compared with text-based patient information sheets alone. The business case for compliant video is compelling; the execution risk is manageable only with the right production team.

Regulatory and Compliance Constraints

Pharmaceutical video production in the UK is shaped by a layered compliance framework. Understanding each layer before production begins is non-negotiable.

ABPI Code of Practice (22nd Edition): All promotional video directed at HCPs must be certifiable under Clause 14 — meaning a medical signatory (usually the Medical Director or a designated company physician) must formally certify that the content is accurate, balanced, and does not mislead. Scripts must be certified before filming begins. Any change post-certification requires re-certification.
MHRA Advertising Regulations: Patient-facing content for prescription-only medicines is prohibited under the Human Medicines Regulations 2012 unless it falls within the exemptions for disease-awareness campaigns. Patient-support and disease-awareness videos must not reference a specific POM by name or encourage its use.
ICH E6 GCP and Clinical Trial Regulations: Clinical-trial recruitment videos constitute part of the participant information process. In the UK post-Brexit regulatory environment, they must be reviewed and approved by the relevant Research Ethics Committee (REC) and, for CTIMP trials, the MHRA. This process adds 8–16 weeks to the production timeline and must be factored into the project plan.
Patient Informed Consent for Filming: Any patient who appears in a film — whether in a clinical trial recruitment video or a patient-support production — must provide written informed consent using a form approved by the REC or the company's medical-legal review team. Consent covers the specific footage, the channels on which it will be used, and the duration of use. Consent cannot be presumed from participation in a related study.
Veeva PromoMats / MLR Workflows: Most large pharma and biotech companies route video content through a medical-legal-regulatory (MLR) review system, frequently Veeva PromoMats. This means every script draft, every visual asset, and the final cut must be uploaded, reviewed and approved within the MLR system before use. We work within your existing MLR workflow rather than alongside it.

Production Workflow for Pharmaceutical Video

A standard compliant pharma production runs 10–16 weeks from brief to certified delivery. Clinical-trial recruitment films requiring REC approval run 20–30 weeks.

Regulatory Scoping (Week 1–2): Define promotional versus non-promotional classification, identify applicable ABPI clauses, confirm whether HCP or patient audience triggers MHRA constraints, establish MLR workflow and medical signatory contacts.
Script Development (Week 2–4): Claims matrix developed in parallel with scriptwriting. Every efficacy or safety claim mapped to an approved reference (SmPC, published trial data, NICE guidance). Scripts submitted to MLR at first draft stage.
Medical-Legal-Regulatory Review (Week 4–8): First MLR cycle typically returns 2–3 rounds of comments. We accommodate up to three revision cycles within the standard timeline. ABPI certification obtained before camera rolls.
Patient/HCP Consent (concurrent with MLR): Consent pack designed and approved by medical-legal. Patients identified by clinical team or patient advocacy organisation. Minimum 4-week lead time for consent return.
Pre-Production and Shoot (Week 8–10): Location access protocols agreed with clinical site or manufacturing facility. DBS-cleared crew where site requires. All visual claims presented on-screen cross-referenced to certified script.
Post-Production and Final MLR (Week 10–14): Edit reviewed against certified script frame by frame. Supers, footnotes and prescribing-information references added per ABPI requirements. Final cut uploaded to PromoMats for formal sign-off.
Distribution and Archiving (Week 14–16): Delivered in broadcast MP4, web-optimised H.264 and closed-caption SRT. ABPI-compliant metadata and certification records archived for 5 years per Code requirements.

Pricing Tiers for Pharmaceutical Video

UK Pharmaceutical Video — Budget Ranges by Format
Format	Audience	Typical Runtime	Budget Range (£)	Key Compliance Driver
HCP Promotional Film	Prescribers / MSLs	3–6 min	18,000–45,000	ABPI Clause 14 certification
Clinical Trial Recruitment	Prospective participants	2–4 min	22,000–55,000	REC approval + MHRA CTIMP review
Disease Awareness Campaign	General public	60–90 sec	12,000–30,000	MHRA no-POM-name rule
Patient Support / PSP Film	Patients on therapy	3–5 min	15,000–35,000	ABPI non-promotional classification
Internal Training / MSL Briefing	Field force / MSLs	5–20 min	8,000–25,000	Internal use — MLR still recommended
Congress / Conference Film	HCPs at event	2–5 min	14,000–32,000	ABPI Clause 22 (meetings and hospitality)

Regulatory review cycles — script certification, REC submission, PromoMats workflow — add a non-reducible cost of £3,500–£8,000 to any project, regardless of format. This is built into all estimates above and cannot be removed.

Consent and Clearance Checklist

Medical signatory identified and available for Clause 14 certification before shoot date
Claims matrix drafted; every efficacy/safety claim referenced to SmPC or published peer-reviewed data
Patient consent forms approved by medical-legal review team (or REC for trial recruitment)
Site access agreement signed by clinical facility if filming in a hospital or clinic
DBS checks completed for crew members requiring site access
REC approval obtained (CTIMP trials only — allow 8–16 weeks)
MHRA notification or approval confirmed where required
MLR workflow mapped: PromoMats job number assigned, reviewers briefed
Post-production review against certified script completed before PromoMats final submission
5-year archiving plan for certification records and consent documentation

How to Choose a Pharmaceutical Video Production Partner

Not every production company can navigate the pharmaceutical compliance environment. When evaluating partners, ask these questions.

Have they produced ABPI-certifiable content for a top-20 pharma company? Request documentary evidence — not testimonials.
Do they understand the difference between promotional and non-promotional classification under the ABPI Code, and can they advise on which applies to your brief?
Have they worked within a Veeva PromoMats or similar MLR workflow? Generic cloud storage is not a compliant substitute.
Do they have a DBS-cleared crew available for clinical site shoots?
Can they produce a patient consent pack and advise on REC submission requirements, or will they refer you back to your clinical team for every document?

Make It Real Production has produced compliant pharmaceutical video for companies operating under the ABPI Code since 2018. Our standard project team includes a regulatory coordinator who works alongside the creative director on every pharma project — not as a separate compliance bolt-on, but as part of the core production team.

Frequently Asked Questions

Does every pharma video need ABPI certification?: Formal ABPI Clause 14 certification is required for promotional content directed at HCPs. Internal training materials, disease-awareness films not referencing a specific POM, and non-promotional patient-support programmes fall outside the promotional definition — but we recommend MLR review for all pharma video regardless of classification, as the line between promotional and non-promotional is routinely tested at PMCPA.
How long does REC approval take for a clinical-trial recruitment video?: Standard Research Ethics Committee review takes 8–12 weeks from submission. Full board review for higher-risk studies can take 14–16 weeks. Expedited review is available in limited circumstances. Your clinical team's Research Manager should initiate the IRAS submission as early as possible — we provide all documentation required from the production side within week 2 of the project.
Can patients be filmed without appearing on screen?: Yes. Voice-over narration, written patient testimonials presented as on-screen text, and animated patient-journey films are all compliant alternatives that remove the personal data risk associated with filmed patient appearances. For rare disease indications where the patient community is small and identifiable, we strongly recommend these approaches even when patients consent to filming.
What happens if our certifying physician changes after filming?: If the medical signatory who certified the script is no longer in post, the content must be re-certified by a new signatory before it can continue to be used promotionally. This is a ABPI Code requirement, not a make-it-real policy. We flag this risk at project outset and recommend filming content that can remain valid for 2–3 years without modification, reducing re-certification frequency.
Can you work with our existing PromoMats workflow?: Yes. We are familiar with Veeva PromoMats and can upload assets, respond to reviewer comments and resubmit within your system. We request job number and access credentials at kick-off. If your company uses a different MLR platform (ZING, Zinc, Aprimo), we adapt accordingly — the workflow logic is the same across all major MLR systems.
What is the typical number of MLR revision cycles?: Two to three rounds of substantive revision is standard for promotional HCP content. Internal training materials typically clear in one round. Clinical-trial recruitment films reviewed by REC often require adjustments to plain-language wording — we allow up to four rounds within the standard project budget. Beyond four rounds, additional revision fees apply at £650 per round.
Do you film in hospitals and clinical trial sites?: Yes. We have filmed in NHS Trust facilities, private hospital sites and specialist clinical research units. All crew members hold current DBS Enhanced certificates where site access requires it. We negotiate site access agreements directly with the Trust R&D office or site management team. Typical site access fees (paid to the facility) range from £0 to £1,200 per shoot day and are passed through at cost.
How are safety updates handled if an SmPC changes post-production?: Any change to the SmPC that affects a certified claim requires immediate withdrawal of the affected video from promotional use. We version-control all scripts and can produce targeted re-edits covering specific claims at £600–£1,800 per amended segment — significantly less than a full reshoot. We recommend annual content audits for all certified pharma video as standard practice.